GLP-1 receptor agonists are widely studied for their role in appetite regulation and glucose metabolism. One of their primary mechanisms is slowing gastric emptying, which means food remains in the stomach longer before moving through the digestive system.
This effect is well documented in clinical research and plays a role in how these therapies influence satiety and digestion.
A study published in Cardiovascular Endocrinology & Metabolism found that GLP-1 receptor agonists slow gastric emptying and contribute to increased feelings of fullness.
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/
Because digestion slows, dietary choices and eating patterns can influence how the body responds.
Some individuals report gastrointestinal symptoms while using GLP-1 therapies, including:
• nausea
• bloating
• reflux
• abdominal discomfort
Clinical research has shown that these effects are commonly related to how GLP-1 therapies interact with the digestive system.
A review in The Lancet notes that gastrointestinal symptoms are among the most frequently reported effects during GLP-1 therapy, particularly during dose adjustments.
Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC12532569/
These symptoms may be influenced by both the therapy itself and individual dietary habits.
Because GLP-1 therapies slow gastric emptying, certain eating patterns may increase digestive discomfort.
Research suggests that larger meal sizes and high-fat foods can delay gastric emptying further and increase gastrointestinal symptoms.
A study in The American Journal of Clinical Nutrition found that high-fat meals significantly slow gastric emptying compared to lower-fat meals.
Source: https://ajcn.nutrition.org/article/S0002-9165(23)30260-0/fulltext
When combined with GLP-1 therapy, this effect may contribute to increased digestive discomfort for some individuals.
While individual responses vary, some general strategies are often discussed in clinical settings:
Eating smaller portions may help reduce the burden on digestion when gastric emptying is slower.
Taking time to eat may support digestion and help individuals better recognize fullness cues.
Meals that include protein, fiber and moderate fat are often discussed in relation to satiety and digestion.
Maintaining adequate hydration may support overall digestive function.
These strategies are typically discussed as part of a broader, provider-guided approach.
GLP-1 therapies are studied for their effects on appetite regulation, glucose metabolism and weight-related outcomes.
A large clinical trial published in The New England Journal of Medicine evaluated semaglutide and its effects on weight management and metabolic outcomes.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
As with any therapy, individual experiences vary and should be evaluated within the context of medical guidance.
Because responses to GLP-1 therapies can differ, working with a licensed healthcare provider is important. Providers may evaluate:
• medical history
• current medications
• lifestyle habits
• individual tolerance and response
TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers who can discuss individualized approaches to wellness and metabolic health.
Understanding how GLP-1 therapies interact with digestion can help individuals make more informed choices about their eating habits and overall wellness strategies.
For individuals exploring these therapies, combining provider guidance with thoughtful lifestyle habits may support a more comfortable and informed experience.
If you are interested in learning more, TeleWellnessMD® connects patients with licensed healthcare professionals who can discuss personalized approaches based on individual needs.
Important Disclaimer
The information in this article is provided for educational purposes only and is not intended as medical advice. Individual experiences and results may vary. TeleWellnessMD® is a technology platform that connects patients with licensed healthcare providers. TeleWellnessMD® does not practice medicine, provide medical advice or dispense medications. Compounded medications have not been evaluated by the U.S. Food and Drug Administration (FDA) as safe or effective for the treatment of any medical condition. Prescription required. Results may vary. Patients must be 18 years or older.